JLE

e-VEGF-IMMUNO-actu

MENU

Oncologie : Y a-t-il une place pour les combinaisons ? Volume 11, issue 4, Octobre 2016

  • [1] Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263-72.
  • [2] Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol. 2015;5:202.